We speculate that GATA1 confers gemcitabine resistance in pancreatic cancer not only by activating Bcl-XL, but also by retaining proliferative potential of PDAC cancer following treatment with gemcitabine. Here, BCL2L1 is linked to familial pancreatic carcinoma.